Researchers examined 161 patients and used an antibody called IMAB362.
Here are five points:
1. The researchers found the median survival of patients undergoing the antibody therapy treatment plus standard chemotherapy was more than 13 months.
2. Comparatively, patients who only received chemotherapy had a median survival of 8.4 months.
3. The researchers also found patients who had the highest level of claudin 18.2, a protein on cancer cells, in tumors before undergoing the new antibody therapy treatment had a median survival of 17 months. The IMAB362 antibody targets claudin 18.2.
4. The researchers are planning a larger phase 3 study in stomach cancer patients for early 2017.
5. The American Cancer Society estimates physicians will diagnose more than 26,000 stomach cancer cases in U.S. residents this year, and the disease will kill almost 11,000 residents.
More articles on GI & endoscopy:
6 GI physicians in the news — June 3, 2016
Dr. Robert Beart receives 2 honors: 5 things to know
European Commission approves Afinitor for GI NETs — 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
